181 related articles for article (PubMed ID: 36301970)
1. Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina.
Posadas-Martinez ML; Aguirre MA; Brulc E; Saez MS; Sorroche P; Machnicki G; Fernandez M; Nucifora EM
PLoS One; 2022; 17(10):e0274578. PubMed ID: 36301970
[TBL] [Abstract][Full Text] [Related]
2. Incidence rate of amyloidosis in patients from a medical care program in Buenos Aires, Argentina: a prospective cohort.
Aguirre MA; Boietti BR; Nucifora E; Sorroche PB; González Bernaldo de Quirós F; Giunta DH; Posadas-Martínez ML
Amyloid; 2016 Sep; 23(3):184-187. PubMed ID: 27470486
[TBL] [Abstract][Full Text] [Related]
3. AL amyloidosis in Argentina: hospital Italiano de Buenos Aires.
Nucifora EM; Aguirre MA; Sorroche P; Saez MS; Fantl D; Rocca JA; Perez de Arenaza D; Varela CF; Greloni G; García Rivello H; Basquiera AL; Alberbide JA; Giunta DH; Boietti BR; Posadas Martínez ML
Amyloid; 2019; 26(sup1):99-100. PubMed ID: 31343332
[No Abstract] [Full Text] [Related]
4. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
[TBL] [Abstract][Full Text] [Related]
5. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study.
Shen KN; Zhang CL; Tian Z; Feng J; Wang YN; Sun J; Zhang L; Cao XX; Zhou DB; Li J
Amyloid; 2019 Jun; 26(2):66-73. PubMed ID: 31074308
[No Abstract] [Full Text] [Related]
7. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018.
Palladini G; Schönland S; Merlini G; Milani P; Jaccard A; Bridoux F; Dimopoulos MA; Ravichandran S; Hegenbart U; Roeloffzen W; Cibeira MT; Agis H; Minnema MC; Bergantim R; Hájek R; João C; Leonidakis A; Cheliotis G; Sonneveld P; Kastritis E; Wechalekar A
Blood Cancer J; 2023 Jan; 13(1):19. PubMed ID: 36697388
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases.
Dispenzieri A; Zonder J; Hoffman J; Wong SW; Liedtke M; Abonour R; D'Souza A; Lee C; Cote S; Potluri R; Ammann E; Tran N; Lam A; Nair S
Amyloid; 2023 Jun; 30(2):161-168. PubMed ID: 36282014
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and clinical outcomes of light-chain amyloidosis in Sweden: A nationwide population-based study.
Mellqvist UH; Cai Q; Hester LL; Grövdal M; Börsum J; Rahman I; Ammann EM; Hansson M
Eur J Haematol; 2023 Nov; 111(5):697-705. PubMed ID: 37533343
[TBL] [Abstract][Full Text] [Related]
10. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Blood; 2020 Dec; 136(23):2620-2627. PubMed ID: 33270858
[TBL] [Abstract][Full Text] [Related]
11. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
12. Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan.
Shimazaki C; Hata H; Iida S; Ueda M; Katoh N; Sekijima Y; Ikeda S; Yazaki M; Fukushima W; Ando Y
Intern Med; 2018 Jan; 57(2):181-187. PubMed ID: 29093404
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.
Huang X; Wang Q; Chen W; Ren G; Liu Z
Amyloid; 2016; 23(1):51-7. PubMed ID: 26862817
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK.
Sharpley FA; Manwani R; Petrie A; Mahmood S; Sachchithanantham S; Lachmann HJ; Martinez De Azcona Naharro A; Gillmore JD; Whelan CJ; Fontana M; Cohen O; Hawkins PN; Wechalekar AD
Eur J Haematol; 2021 Apr; 106(4):537-545. PubMed ID: 33460466
[TBL] [Abstract][Full Text] [Related]
16. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
[TBL] [Abstract][Full Text] [Related]
17. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
18. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
19. A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan.
Fuchida SI; Ide D; Taminishi-Katsuragawa Y; Suga T; Matsui-Maegawa S; Maruyama N; Iwamura Y; Kitamura Y; Okawa Y; Okano A; Hatsuse M; Murakami S; Shimazaki C
Int J Hematol; 2020 Jun; 111(6):803-811. PubMed ID: 32020505
[TBL] [Abstract][Full Text] [Related]
20. Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib.
Shen KN; Miao HL; Zhang CL; Feng J; Zhang L; Cao XX; Zhou DB; Wei S; Li J
Leuk Lymphoma; 2021 Apr; 62(4):874-882. PubMed ID: 33215569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
